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INTRODUCTION
Head and neck cancers are placed among the 
most common neoplasm worldwide [1, 2]. 
They can develop in the oral cavity, pharynx, 
paranasal sinuses, nasal cavity, larynx, salivary 
glands and the skin of head and neck [3]. In 
our study we investigated two types of head 
and neck cancer with different origin, natural 
history and clinical outcome – squamous cell 
carcinomas (SCCs) of the oral cavity represent-
ing highly invasive malignancies, and basal cell 
carcinomas (BCCs) of the skin, a class of usu-
ally non-aggressive tumors.
Oral SCCs account for approximately 
500,000 new cases worldwide, making them 
the 6th most common cancer type [1, 2, 4]. 
The overall 5-year survival rate for oral SCCs 
is merely 50%. Almost 85% of patients are al-
cohol or tobacco abusers or both [4]. Other 
causative agents include chewing tobacco, ill-
fitting dental appliances, chronic candidiasis, 
viral infections (mainly involving certain HPV 
types) and poor oral hygiene [2, 3].
BCCs mostly occur on sun-exposed areas 
of the body, such as the head and neck (80% 
of cases). Acute and chronic skin exposure to 
ultraviolet radiation is supposed to be a cru-
cial factor in their development [5, 6]. Most 
of them have a superficial or nodular growth 
pattern. Although mortality rates are low, 
BCCs may grow per continuitatem and cause 
severe local destruction. Metastasis occurs in 
less than 1% [7, 5]. Although most BCCs occur 
in elderly persons, the incidence in young pa-
tients is increasing lately in a disproportionate   
mode [7, 8].
It is well known that head and neck carcino-
genesis is a multifactorial process in which en-
vironmental etiologic factors are coupled with 
alterations in oncogenes and tumor suppres-
sor genes [4]. Recently, research has also been 
focused on genetic factors that can modulate 
cancer susceptibility such as common DNA 
polymorphisms [9]. Functional single nucle-
otide polymorphisms (SNPs) in the survivin 
gene have recently emerged as potential risk 
factors for the development of several malig-
nant diseases.
Survivin is a member of the inhibitor of ap-
optosis (IAP) gene family. IAPs are anti-apoptot-
ic proteins that inhibit initiator (caspase-9) and 
effector caspases (caspase-3 and 7) and thus pre-
vent apoptosis [10, 11]. Beside its involvement in 
the regulation of apoptosis, survivin is involved 
in cell cycle progression, and microtubule stabil-
ity, thus contributing to ordered development 
and cellular homeostasis [12].
SUMMARY
Introduction Association studies have shown that gene polymorphisms in various classes of genes can 
modulate cancer risk. The -31G/C polymorphism in the promoter of survivin gene, affects the expression 
of the anti-apoptotic protein survivin which in turn may predispose an individual to some types of cancer.
Objective The aim of the study was to determine whether the survivin promoter -31G/C polymorphism 
could be a susceptibility factor for squamous cell carcinoma (SCC) of the oral cavity and basal cell car-
cinoma (BCC) of the skin.
Methods The DNA obtained from 88 patients with SCC, 60 patients with BCC and 111 healthy individuals 
was subjected to polymerase chain reaction-restriction fragment length polymorphism analysis (PCR-
RFLP) in order to determine genotype and allele frequencies in patients and control groups. Logistic 
regression was used for cancer risk assessment.
Results The following distribution of genotypes was obtained: CC genotype 15% in the SCC group, 
13% in the BCC group and 12% in controls; CG genotype 41% in SCCs, 35% in BCCs, 48% in controls; 
GG genotype 44% in SCCs, 52% in BCCs and 40% in controls. Allelic frequencies were as follows: G allele 
0.65 in SCCs, 0.69 in BCCs and 0.64 in the control group; C allele 0.35 in SCCs, 0.31 in BCCs and 0.36 in the 
control group. There was no statistically significant difference in allele or genotype frequencies between 
the patients and controls (p>0.05).
Conclusion In Serbian population, -31G/C polymorphism in the promoter of the survivin gene cannot 
be considered as a risk factor for oral squamous cell carcinoma and skin basal cell carcinoma.
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Structurally, the human survivin gene comprises four 
exons separated by three introns spanning 14.7-kb, which 
encodes a 16.5-kDa protein [13, 14]. Survivin is expressed 
in a cell-cycle-dependent manner, with a peak in the G2/M 
phase of the cell cycle, when it is associated with the micro-
tubules of the mitotic spindle, and exhibits a rapid down-
regulation in the G1 phase [15]. This is controlled at the 
transcriptional level and mediated by cell cycle-dependent 
elements (CDEs) and cell cycle homology regions (CHRs) 
located in the proximal region of the survivin promoter 
[16]. Several single-nucleotide polymorphisms have been 
identified within the promoter region of the survivin gene, 
one of which is located at the CDE/CHR repressor binding 
site (-31G/C). This polymorphism has been associated with 
overexpression of survivin at both messenger RNA (mRNA) 
and protein levels in a number of cancer cell lines [17].
Survivin is strongly expressed in embryonic and fetal tis-
sues but is undetectable in most terminally differentiated 
normal adult tissues [18]. By contrast, dramatic overexpres-
sion of survivin compared to normal tissues was demon-
strated in tumors of lung, breast, colon, stomach, esophagus, 
pancreas, bladder, nonmelanoma skin cancers, and others 
[16]. In genome-wide searches, survivin constituted the 
fourth top “transcriptome” in cancers of colon, lung, brain, 
breast, and melanoma, but its expression was low or unde-
tectable in the normal tissue of the same specimens [19].
OBJECTIVE
The aim of this study was to investigate a possible associa-
tion between survivin promoter single nucleotide polymor-
phisms (SNP) at position -31G/C known to be a regulator of 
survivin expression, and the susceptibility for the develop-
ment of two types of HNC in the Serbian population.
METHODS
Patients
The study population comprised 88 patients with oral sq-
uamous cell carcinoma (53 males, 27 females, mean age, 69 
years) and 60 patients (26 males, 34 females, mean age 71 
years) with basal cell carcinoma of the skin, histologically 
confirmed, who underwent surgical resection at the Clinic 
for Maxillofacial Surgery, Faculty of Dental Medicine, Uni-
versity of Belgrade. The study protocol was approved by 
the institutional Ethical Committee.
Survivin -31 G/C genotyping
Genomic DNA was isolated from the tissue of histological-
ly negative margins from 88 patients with SCC and 60 pa-
tients with BCC using the organic extraction protocol. For 
the control group, genomic DNA was isolated from buc-
cal swabs of 111 healthy individuals using QIAmp DNA 
Mini Kit (Qiagen, GmbH, Germany), as recommended   
by the manufacturer. Patients and controls were sex and 
age matched. The survivin promoter polymorphism -31G/
C genotyping was performed using a polymerase chain 
reaction-restriction fragment length polymorphism (PCR-
RFLP) technique. A 151 base pair fragment, surround-
ing the -31 position, was amplified using the following 
primers: 5’-AAGAGGGCGTGCGCTCCCGACA-3’ and 
5’-GAGATGCGGTGGTCCTTGAGAAA-3’. The PCR 
was performed in a total volume of 20 µl containing 2 µl 
of 10X PCR buffer (MBI Fermentas, Lithuania), 1.5 µl of 
MgCl2 , 0.2 mM dNTPs, 0.375 µM of each primer, 200 ng 
of genomic DNA and 1 unit of Taq DNA polymerase (MBI 
Fermentas, Lithuania). The amplification conditions were 
as follows: initial denaturation at 95°C for 5 minutes, fol-
lowed by 35 cycles consisting of denaturation at 94°C for 
45 s, annealing at 60°C for 45 s, elongation at 72°C for 1 
min, and a final elongation at 72°C for 10 min. The diges-
tion was carried using 5 units of Msp I (MBI Fermentas, 
Lithuania), resulting in products of 90 and 61 base pairs 
(bp) for the CC genotype, three fragments of 151, 90 and 
61 bp for the GC genotype and a 151 bp fragment for the 
GG genotype. Genotypes were confirmed by randomly re-
genotyping 10% of samples. There were no discrepancies 
between genotypes determined in duplicate.
Statistical analysis
Chi square test and Fisher exact test were used to deter-
mine possible differences in the genotype and allele fre-
quencies. The association of -31 survivin variants with risk 
of disease was examined by use of unconditional logistic 
regression analysis to calculate odds ratios (OR) and their 
95% confidence intervals (CI). P values of <0.05 were con-
sidered statistically significant. The expected frequency of 
survivin variants in controls was analyzed by the Hardy-
Weinberg equilibrium test. Calculations were performed 
with the statistical package Stata V6.
RESULTS
The interpretation of the characteristic electrophoretic 
bands following PCR-RFLP and determination of indi-
vidual genotypes in healthy subjects and patients with SCC 
and BCC, along with observed allele frequencies and risk 
estimate for the -31G/C polymorphism in the survivin 
gene are given in Tables 1 and 2.
Genotype and allele frequencies at position -31 did not 
show significant difference between patients and controls.
DISCUSSION
Survivin, a crucial anti-apoptotic factor, also plays an im-
portant role in cell cycle regulation. Considerable evidence 
suggests that elevated expression of survivin may promote 
tumorigenesis, and indeed survivin is highly expressed in 
common human cancers [20-24].  
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Functional polymorphisms influencing survivin ex-
pression may be considered as risk factors for carcino-
genesis. Despite the existing data on the association of 
survivin gene promoter polymorphism -31G/C and cancer 
susceptibility, this association is not universally observed. 
Depending on cancer types, as well as on patients’ eth-
nic origin, published results are quite divergent. A recent 
meta-analysis by Srivastava et al. [25] indicates that an 
increased risk of cancer related to this SNP was significant 
only in the Asian population.
Though the comprehensive experiments of Xu et al. 
[17] on a large number of cancer cell lines has shown that 
survivin overexpression is due to the presence of the G 
allelic variant, strangely, the majority of clinical studies 
have found the opposite, i.e. that the C allele is related to 
survivin overexpression and to a higher risk for cancer de-
velopment. Jang et al. [26] identified that individuals with 
at least one G allele at position -31 were at a significantly 
decreased risk of lung cancer compared to individuals with 
the -31C/C genotype. Cheng et al. [27] found that the fre-
quency of C allele and C/C genotype were significantly 
higher in patients with gastric cancer than in healthy in-
dividuals. In the study of Gazouli et al. [28], -31C/C geno-
type and -31C allele were associated with a significantly 
increased risk for colorectal cancer (CRC. They observed 
a strong association between -31C/C genotype and ad-
vanced stages (III and IV) of the disease and unfavorable 
prognosis. However, several studies, such as the one in-
volving Brazilian patients with gastric carcinoma, showed 
the G allele to be responsible for an increased risk of the 
development of diffuse tumor types and for the early onset 
of the disease [29]. Similarly, Yang et al. [30] demonstrated 
that carriers of the G allele were at a higher risk of distal 
and well-differentiated gastric cancer. The results of our 
previous study, conducted on keratocystic odontogenic 
tumors (KCOTs) also showed that the GG genotype and 
the G allele are associated with an increased risk of KCOT 
development [31].
Finally, a third group of studies, including the present 
study on HNCs, failed to establish any influence of the 
-31 G/C SNP on cancer development. Wagner et al. [32], 
for instance, were unable to demonstrate association of 
-31G/C polymorphism with acute myeloid leukemia. It 
seems also that this SNP is irrelevant as potential risk fac-
tor for cervical carcinogenesis [33].
The fact that there is no straightforward relationship be-
tween survivin gene variants, its expression at the mRNA 
level and the expression at protein level, points to a very 
complex regulation of survivin production and function. 
And although survivin is recognized as a prognostic marker 
for some tumors, controversies are present in immunohis-
tochemical analyses as well, regarding the prognostic sig-
nificance of cytoplasmic versus nuclear survivin expression.
CONCLUSION
In Serbian population the polymorphism -31G/C in the 
survivin gene promoter does not modulate the susceptibil-
ity for head and neck tumor development.
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Table 1. Genotype and allele frequencies and logistic regression 
analysis data for the survivin promoter -31G/C polymorphism in 
squamous cell carcinoma (SCC) of oral cavity
Parameter SCC
(n=60)
Control
(n=111) OR 95% CI p
G/G 39 (44%) 45 (40%) 1.00 Reference
C/G 36 (41%) 53 (48%) 0.78 0.43-1.43 0.261
C/C 13 (15%) 13 (12%) 1.15 0.48-2.78 0.462
C/G+C/C 49 (56%) 66 (60%) 0.86 0.49-1.51 0.348
G 0.65 0.64 1.00 Reference
C 0.35 0.36 0.96 0.54-1.71 0.500
OR – odds ratio; CI – confidence interval; p – probability; n – number of 
individuals
Table 2. Genotype and allele frequencies and logistic regression 
analysis data for the survivin promoter -31G/C polymorphism in basal 
cell carcinoma (BCC) of oral cavity 
Parameter BCC
(n=60)
Control
(n=111) OR 95% CI p
G/G 31 (52%) 45 (40%) 1.00 Reference
C/G 21 (35%) 53 (48%) 0.58 0.29-1.14 0.077
C/C 8 (13%) 13 (12%) 0.89 0.33-2.41 0.515
C/G+C/C 29 (48%) 66 (60%) 0.64 0.34-1.20 0.108
G 0.69 0.64 1.00 Reference
C 0.31 0.36 0.80 0.44-1.44 0.275
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КРАТАК САДРЖАЈ
Увод До  ка  за  но је да по  ли  мор  фи  зми у раз  ли  чи  тим кла  са-
ма ге  на мо  гу да по  ве  ћа  ју ри  зик за раз  вој ма  лиг  них ту  мо  ра, 
из  ме  ђу оста  лих и сква  мо  це  лу  лар  ног кар  ци  но  ма (SCC) усне 
ду  пље и ба  зо  це  лу  лар  ног кар  ци  но  ма (BCC) ко  же. Сур  ви  вин је 
би  функ  ци  о  нал  ни про  те  ин-ин  хи  би  тор апоп  то  зе и ре  гу  ла  тор 
ће  лиј  ског ци  клу  са. От  кри  ве  но је ви  ше функ  ци  о  нал  них по  ли-
мор  фи  за  ма у овом ге  ну, а је  дан од кључ  них је по  ли  мор  фи-
зам G/C на по  зи  ци  ји -31, за ко  ји је по  ка  за  но да је мо  ду  ла  тор 
екс  пре  си  је сур  ви  ви  на и да до  при  но  си по  ве  ћа  њу ри  зи  ка од 
обо  ле  ва  ња од раз  ли  чи  тих ти  по  ва ту  мо  ра.
Циљ ра  да Циљ ра  да је био да се ана  ли  зи  ра уче  ста  лост ге-
но  ти  по  ва и але  ла за -31G/C по  ли  мор  фи  зам ге  на за сур  ви  вин 
код осо  ба обо  ле  лих од SCC и BCC и код здра  вих ис  пи  та  ни  ка. 
Ло  ги  стич  ком ре  гре  си  о  ном ана  ли  зом ис  пи  та  на је по  ве  за-
ност овог по  ли  мор  фи  зма и ри  зи  ка за на  ста  нак SCC и BCC.
Ме  то  де ра  да Уче  ста  ло  сти але  ла и ге  но  ти  по  ва код 88 осо  ба 
обо  ле  лих од SCC, 60 осо  ба обо  ле  лих од BCC и 111 здра  вих 
ис  пи  та  ни  ка од  ре  ђе  не су лан  ча  ном ре  ак  ци  јом по  ли  ме  ра  зе 
и ре  стрик  ци  о  ном ана  ли  зом. Ло  ги  стич  ком ре  гре  си  јом про-
це  ње  на је скло  ност ка раз  во  ју SCC и BCC.
Ре  зул  та  ти Ге  но  тип CC је утвр  ђен код 15% ис  пи  та  ни  ка са 
SCC, 13% са BCC и 12% зда  вих осо  ба. Ге  но  тип CG је за  бе  ле-
жен код 41% ис  пи  та  ни  ка са SCC, 35% са BCC и 48% здра-
вих осо  ба. Ге  но  тип GG је от  кри  вен код 44% осо  ба са SCC, 
52% са BCC и 40% здра  вих ис  пи  та  ни  ка. Уче  ста  лост G-але  ла 
би  ла је сле  де  ћа: 0,65 код ис  пи  та  ни  ка са SCC, 0,69 код ис-
пи  та  ни  ка са BCC и 0,64 у гру  пи здра  вих осо  ба. Уче  ста  лост 
C-але  ла би  ла је: 0,35 код ис  пи  та  ни  ка са SCC, 0,31 код ис  пи-
та  ни  ка са BCC и 0,36 у гру  пи здра  вих осо  ба. Ни  је би  ло ста-
ти  стич  ки зна  чај  не раз  ли  ке у рас  по  де  ли ге  но  ти  по  ва и але-
ла из  ме  ђу бо  ле  сни  ка с кар  ци  но  ми  ма и здра  вих ис  пи  та  ни  ка   
(p>0,05).
За  кљу  чак По  ли  мор  фи  зам -31G/C у про  мо  то  ру ге  на за сур-
ви  вин не мо  же се сма  тра  ти фак  то  ром ри  зи  ка за раз  вој ова 
два ти  па ту  мо  ра.
Кључ  не ре  чи: по  ли  мор  фи  зам; сур  ви  вин; про  мо  тор; ту  мо  ри 
гла  ве и вра  та
Примљен • Received: 21/03/2012    Прихваћен • Accepted: 18/06/2012
Анализа полиморфизма у промотору гена за сурвивин као могућег фактора 
ризика за настанак тумора главе и врата
Марија Костић1, Нађа Николић1, Бранислав Илић1, Јелена Чаркић1, Сања Миленковић2, Мирослав Вукадиновић3
1Институт за хуману генетику, Стоматолошки факултет, Универзитет у Београду, Београд, Србија;
2Служба клиничке патологије, Клиничко-болнички центар Земун, Београд, Србија;
3Клиника за максилофацијалну хирургију, Стоматолошки факултет, Универзитет у Београду, Београд, Србија
8.  Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley 
CC, Weaver AL, et al. Incidence of basal cell and squamous cell 
carcinomas in a population younger than 40 years. JAMA. 2005; 
294(6):681-90.
9.  Wünsch Filho V, Zago MA. Modern cancer epidemiological research: 
genetic polymorphisms and environment. Rev Saude Publica. 2005; 
39(3):490-7.
10.  Thompson CB. Apoptosis is the pathogenesis and treatment of 
disease. Science. 1995; 267(5203):1456-62.
11.  Raff M. Cell suicide for beginners. Nature. 1998; 396(6707):119-22.
12.  Altieri DC. Survivin, versatile modulation of cell division and 
apoptosis in cancer. Oncogene. 2003; 22(53):8581-9.
13.  Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of 
mitosis and apoptosis and novel target for cancer therapeutics. Clin 
Cancer Res. 2008; 14(16):5000-5.
14.  Marioni G, Bedogni A, Giacomelli L, Ferraro SM, Bertolin A, Facco 
E, et al. Survivin expression is significantly higher in pN+ oral and 
oropharyngeal primary squamous cell carcinomas than in pN0 
carcinomas. Acta Otolaryngol. 2005; 125(11):1218-23.
15.  Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. 
Control of apoptosis and mitotic spindle checkpoint by survivin. 
Nature. 1998; 396(6711):580-4.
16.  Altieri DC, Marchisio PC, Marchisio C. Survivin apoptosis: an 
interloper between cell death and cell proliferation in cancer. Lab 
Invest. 1999; 79(11):1327-33.
17.  Xu Y, Fang F, Ludewig G, Jones G, Jones D. A mutation found in 
the promoter region of the human survivin gene is correlated 
to overexpression of survivin in cancer cells. DNA Cell Biol. 2004; 
23(9):527-37.
18.  Ambrosini G, Adida C, Alteri DC. A novel anti-apoptosis gene, 
survivin, expressed in cancer and lymphoma. Nat Med. 1997; 
3(8):917-21.
19.  Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al. 
Analysis of human transcriptomes. Nat Genet. 1999; 23(4):387-8.
20.  Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. 
Inhibition of apoptosis by survivin predicts shorter survival rates in 
colorectal cancers. Cancer Res. 1998; 58(22):5071-4.
21.  Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis 
gene, survivin, correlated with tumor cell apoptosis and p53 
accumulation in gastric carcinomas. Cancer Res. 1998; 58(9):1808-12.
22.  Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, et al. 
A novel anti-apoptosis gene: re-expression of surviving messenger 
RNA as a prognostic marker in non-small-cell lung cancers. J Clin 
Oncol. 1999; 17(7):2100-04.
23.  Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M,  
Tanigawa N. Expression of survivin and its relationship to loss of 
apoptosis in breast carcinomas. Clin Cancer Res.  
2000; 6(1):127-34.
24.  Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, et al. 
Expression of survivin in normal, hyperplastic, and neoplastic 
colonic mucosa. Hum Pathol. 2001; 32(1):119-25.
25.  Srivastava K, Srivastava A, Mittal B. Survivin promoter -31G/C 
(rs9904341) polymorphism and cancer susceptibility: a meta-
analysis. Mol Biol Rep. 2012; 39(2):1509-16.
26.  Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, et al. 
Polymorphisms in the survivin gene and the risk of lung cancer. 
Lung Cancer. 2008; 60(1):31-9.
27.  Cheng ZJ, Hu LH, Huang SJ. Correlation of -31G/C polymorphisms 
of survivin promoter to tumorigenesis of gastric carcinoma. Ai 
Zheng. 2008; 27(3):258-63.
28.  Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, 
Papaconstantinou I, Kostakis A, et al. Survivin -31G/C promoter 
polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 
2009; 24(2):145-50.
29.  Borges BD, Burbano RR, Harada ML. Survivin -31C/G polymorphism 
and gastric cancer risk in a Brazilian population. Clin Exp Med. 2011; 
11(3):189-93.
30.  Yang L, Zhu H, Zhou B, Gu H, Yan H, Tang N, et al. The association 
between the survivin C-31G polymorphism and gastric cancer risk 
in a Chinese population. Dig Dis Sci. 2009; 54(5):1021-8.
31.  Andric M, Nikolic N, Boskovic M, Milicic B, Skodric S, Basta Jovanovic 
G, et al. Survivin gene promoter polymorphism -31G/C as a risk 
factor for keratocystic odontogenic tumor development. Eur J Oral 
Sci. 2012; 120(1):9-13.
32.  Wagner M, Schmelz K, Dorken B, Tamm I. Epigenetic and genetic 
analysis of the survivin promoter in acute myeloid leukemia. Leuk 
Res. 2008; 32(7):1054-60.
33.  Borbély ÁA, Murvai M, Szarka K, Kónya J, Gergely L, Hernádi Z, et al. 
Survivin promoter polymorphism and cervical carcinogenesis.  
J Clin Pathol. 2007; 60(3):303-6.